FDA's advisers will weigh Pfizer's evidence in a public meeting this week. If the agency authorises Pfizer's kid shots, then next week, the Centers for Disease Control and Prevention is likely to recommend who should receive them. Study details from Moderna Results from the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the company's vaccine candidate against COVID-19, in children 6 to under 12 years of age: this interim analysis showed a robust neutralising antibody response after two doses of mRNA-1273 at the 50 µg dose level with a favourable safety profile. Moderna plans to submit these data to the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and other global regulators in the near term.